Association of TNFAIP3 With Immune-mediated TTP
Trial statusRecruiting
Trial phaseNot applicable
Trial typeInterventional
Biological sexAll
Age12+
SponsorFondazione IRCCS Ca' Granda, Ospedale Maggiore Policlinico
About this trial
This study aims to investigate whether genetic variation in the TNFAIP3 locus is associated with immune-mediated thrombotic thrombocytopenic purpura (iTTP), and whether such association is mediated by decreased expression of A20 (TNFAIP3). The study includes a case-control design to assess genotype-expression association and a cohort study to evaluate clinical outcomes such as disease relapse.
Eligibility criteria
Qualifiers
Diagnosis of iTTP
Above 12 years of age
Caucasian, Italian origin
Written informed consent to participate in the study
Disqualifiers
Patients who do not meet the above-listed criteria will be excluded from participation in the study.
Trial design
Treatments tested in this trial
- blood sampling
Treatment groups
400 Participants
are divided into 2 treatment groupsSponsors and collaborators
Source ClinicalTrials.gov